LIMN Liminatus Pharma Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of liminatuspharma.com (LIMN)

High R&D costs and strict FDA oversight create significant barriers for competitors. A team of leading immunologists is retained through stock options, ensuring workforce stability. The EV/Sales history demonstrates the market valuation of revenue excluding debt, where the 0.00 mark serves as a key metric. However, the absence of commercial sales makes the financial stability of Liminatus Pharma (LIMN) entirely dependent on new investments.

Company Value to Revenue: Liminatus Pharma Inc. (LIMN) for 11/23/2025 - 11/20/2026

liminatuspharma.com - analytical breakdowns and key metrics (LIMN)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:Liminatus Pharma LIMN
Product sample of Liminatus Pharma

This indicator reflects the total enterprise value relative to sales volume, excluding the impact of debt load to determine an objective market revaluation of the asset. By analyzing the EV/Sales valuation chart, an investor can identify overbought risks, which is critical for Liminatus Pharma (LIMN), whose capitalization relies on the potential of CAR-T therapy against solid tumors and the uniqueness of GCC antigen targeting.

Competitor analysis for Liminatus Pharma

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP